Cart (0 Items)
Your cart is currently empty.
View ProductsStable Isotope Labelled Plozalizumab Biosimilar – Anti-CCR2/CD192 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Isotope Labelled Plozalizumab Biosimilar - Anti-CCR2/CD192 mAb - Research Grade |
|---|---|
| Source | CAS 1610761-46-0 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | MS |
| Aliases /Synonyms | MLN-1202,anti-CCR2,hu1D9 |
| Reference | PX-TA1395-SIL |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
Description of Stable Isotope Labelled Plozalizumab Biosimilar - Anti-CCR2/CD192 mAb - Research Grade
General information on Anti-CCR2/CD192[Homo sapiens] (Plozalizumab) Monoclonal Antibody
Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in the trafficking of monocytes and macrophages to sites of inflammation.
Reviews
Il n’y a pas encore d’avis.